CMP Risk Assessment Publications Plan for July to September 2024
Extended comment period for certain proposed Hotlist changes
FDA Issues FY2023 Report on the State of Pharmaceutical Quality
DEL Bulletin 166: Health Canada’s Approach to Foreign Building Name and Addresses Listed on the Drug Establishment Licence
Annual Compliance Verification Report for 2022-2023
Final Assessment for Aldehydes Group Published
Another Update to the Nitrosamine Guidance Document
Health Canada Published 2023 Hotlist Amendments
Notice of intent to Amend the Domestic Substances List
Final Assessment and Canada Gazette Notice on SNAc Provisions for Piperazine
